These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2895044)

  • 21. Activating and inhibitory NK cell receptors.
    Lanier LL
    Adv Exp Med Biol; 1998; 452():13-8. PubMed ID: 9889954
    [No Abstract]   [Full Text] [Related]  

  • 22. Current understanding of the lymphokine-activated killer cell phenomenon.
    Yagita M; Grimm EA
    Prog Exp Tumor Res; 1988; 32():213-26. PubMed ID: 3131833
    [No Abstract]   [Full Text] [Related]  

  • 23. T cell activation via CD2 [T, gp50] molecules: accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6/T11(1) epitopes.
    Brottier P; Boumsell L; Gelin C; Bernard A
    J Immunol; 1985 Sep; 135(3):1624-31. PubMed ID: 2410496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective activation of gamma/delta + T cell clones by single anti-CD2 antibodies.
    Wesselborg S; Janssen O; Pechhold K; Kabelitz D
    J Exp Med; 1991 Feb; 173(2):297-304. PubMed ID: 1703204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sheep erythrocyte rosetting induces multiple alterations in T lymphocyte function: inhibition of T cell receptor activity and stimulation of T11/CD2.
    Breitmeyer JB; Faustman DL
    Cell Immunol; 1989 Oct; 123(1):118-33. PubMed ID: 2570643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.
    Skibber JM; Lotze MT; Muul LM; Uppenkamp IK; Ross W; Rosenberg SA
    Nat Immun Cell Growth Regul; 1987; 6(6):291-305. PubMed ID: 2896297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E-rosette receptor in human lymphocytes.
    Braun M; Anasetti C; Martin PJ; Hansen JA
    Methods Enzymol; 1987; 150():536-47. PubMed ID: 2893243
    [No Abstract]   [Full Text] [Related]  

  • 28. Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity.
    Nakamura MC; Linnemeyer PA; Niemi EC; Mason LH; Ortaldo JR; Ryan JC; Seaman WE
    J Exp Med; 1999 Feb; 189(3):493-500. PubMed ID: 9927511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and activation requirements of bovine lymphocytes acquiring cytotoxic activity after interleukin-2 treatment.
    Campos M; Rossi CR; Bielefeldt Ohmann H; Beskorwayne T; Rapin N; Babiuk LA
    Vet Immunol Immunopathol; 1992 May; 32(3-4):205-23. PubMed ID: 1352925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The OX-44 molecule couples to signaling pathways and is associated with CD2 on rat T lymphocytes and a natural killer cell line.
    Bell GM; Seaman WE; Niemi EC; Imboden JB
    J Exp Med; 1992 Feb; 175(2):527-36. PubMed ID: 1346273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.
    Nakajima H; Cella M; Bouchon A; Grierson HL; Lewis J; Duckett CS; Cohen JI; Colonna M
    Eur J Immunol; 2000 Nov; 30(11):3309-18. PubMed ID: 11093147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal analysis of the involvement of T11 molecules in antigen receptor-mediated T lymphocyte functions.
    Moretta A; Pantaleo G; Lopez-Botet M; Carrel S; Moretta L
    Behring Inst Mitt; 1985 Aug; (77):39-47. PubMed ID: 2417584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing.
    Uggla CK; Geisberg M; Jondal M; Knowles RW
    Scand J Immunol; 1989 May; 29(5):507-15. PubMed ID: 2567053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Later development of Fas ligand-mediated cytotoxicity as compared with granule-mediated cytotoxicity during the maturation of natural killer cells.
    Nakazawa T; Agematsu K; Yabuhara A
    Immunology; 1997 Oct; 92(2):180-7. PubMed ID: 9415024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin 2-activated killer lymphocytes in man.
    Damle NK; Bradley EC
    Year Immunol; 1988; 3():138-43. PubMed ID: 3327308
    [No Abstract]   [Full Text] [Related]  

  • 37. Dual function of recombinant human CD58: inhibition of T cell adhesion and activation via the CD2 pathway.
    Albert-Wolf M; Meuer SC; Wallich R
    Int Immunol; 1991 Dec; 3(12):1335-47. PubMed ID: 1723296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant interleukin 2 rapidly augments human natural killer cell activity.
    Kabelitz D; Kirchner H; Armerding D; Wagner H
    Cell Immunol; 1985 Jun; 93(1):38-45. PubMed ID: 2581709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CD3 antibodies on cytotoxicity against leukemic cells resistant to activated killer cells.
    Reizenstein P; Vasilopoulos G
    Leuk Res; 1989; 13(6):501-3. PubMed ID: 2528036
    [No Abstract]   [Full Text] [Related]  

  • 40. Regulation of NKG2D ligands: a purposeful but delicate affair.
    Spies T
    Nat Immunol; 2008 Sep; 9(9):1013-5. PubMed ID: 18711442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.